1.本品推薦每七天投予一次，成人單一I.V.的初劑量3.7mg/㎡。其後應計白血球，以測定病人對本品的敏感性。劑量可以漸增但成人不可超過 18.5mg/㎡。小孩不可超過 12.5mg/㎡。但白血球數降至3000/mm2則不可增加劑量。
2.維持劑量每週投予一次，一次的增加劑量少於應有的劑量就會產生上述程度的白血球減少。因此病人接受最大劑量就不會引起白血球減少
施打：
其他注射方式具致命性，限靜脈注射使用。
Absorption
Rapidly absorbed 15 to 30 min following IV triphasic serum decay pattern.
Distribution
Undergoes rapid distribution (from blood to tissue) and extensive tissue binding.
Metabolism
Metabolized by the hepatic P450 3A cytochromes. The metabolite, deacetyl vinblastine, is more active than parent drug.
Elimination
Major route of excretion is the biliary system (liver). Terminal t ½ is 24.8 h.
Special Populations
Hepatic Function Impairment
Toxicity may be enhanced. A dose reduction is recommended. In patients with a direct serum bilirubin value more than 3 mg/dL, a 50% dose reduction is recommended.
CYP-450 inhibitors
Vinblastine elimination may be reduced by CYP-450 enzyme inhibitors.
Erythromycin
Erythromycin may decrease metabolism of vinblastine causing increased toxicity.
Mitomycin
Acute shortness of breath and severe bronchospasm have occurred following concomitant or previous use of mitomycin.
Phenytoin
May reduce phenytoin plasma concentration.
2.非腫瘤引起的白血球減少症。
3.嚴重細菌感染，如有此情形，治療前必須先以殺菌劑或抗生素將其控制。
4.椎管內注射。
2. 在肝功能不全的病患毒性可能會加強。
